



Grant of Options

February 5, 2019 12:00 PM EST

Released : March 05, 2019 07:00

RNS Number : 8081R
MaxCyte, Inc.
05 March 2019

MaxCyte, Inc.
("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - 05 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that on 04 March 2019, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs	
Doerfler, Doug	390,200
Holtz, Ron	177,600
Thompson, J. Stark	26,900
Mandell, Art	26,900
Erck, Stan	26,900
Brooke, Will	26,900
Johnston, John	26,900
Douglas, Richard	26,900
Total	729,200

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 04 March 2019, of 177.50 pence.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

1	Details of the person discharging managerial responsibilities /
----------	--

	person closely associated	
a)	Names	Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard
2	Reason for the notification	
a)	Position/status	Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock
b)	Identification code	US57777K1060
c)	Nature of the transactions	Grant of Options to PDMRs
d)	Price(s) and volume(s)	<p>Doerfler, Doug - 390,200 at an exercise price of 177.50 pence</p> <p>Holtz, Ron - 177,600 at an exercise price of 177.50 pence</p> <p>Thompson, J. Stark - 26,900 at an exercise price of 177.50 pence</p> <p>Mandell, Art - 26,900 at an exercise price of 177.50 pence</p> <p>Erck, Stan - 26,900 at an exercise price of 177.50 pence</p> <p>Brooke, Will - 26,900 at an exercise price of 177.50 pence</p> <p>Johnston, John - 26,900 at an exercise price of 177.50 pence</p> <p>Douglas, Richard - 26,900 at an exercise price of 177.50 pence</p>
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transactions	04 March 2019
f)	Place of the transaction	Outside a trading venue

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immunoncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

+44 (0) 20 7886 2500

Panmure Gordon (UK) Limited

Emma Earl (Corporate Finance)
Freddy Crossley
James Stearns (Corporate Broking)

Financial PR Adviser

+44 (0)20 3709 5700

Consilium Strategic Communicationsmaxcyte@consilium-comms.com

Mary-Jane Elliott

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEANDLEDPNEFF